During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.
‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities. Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’
Topics that are discussed in this e-learning are:
Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL